NEW YORK – Interpace Biosciences said on Monday that it has signed an exclusive license agreement with Rutgers, the State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody, Das-1, in the risk assessment of pancreatic cysts.
The license will give the Parsippany, New Jersey-based firm exclusive commercial rights to the patented technology.